12,622 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by Verition Fund Management LLC

Verition Fund Management LLC bought a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 12,622 shares of the biopharmaceutical company’s stock, valued at approximately $62,000.

Several other large investors have also recently added to or reduced their stakes in the business. Penserra Capital Management LLC increased its stake in Sangamo Therapeutics by 264.2% during the 3rd quarter. Penserra Capital Management LLC now owns 43,877 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 31,829 shares during the period. Nuveen Asset Management LLC increased its position in shares of Sangamo Therapeutics by 208.4% in the 3rd quarter. Nuveen Asset Management LLC now owns 3,355,829 shares of the biopharmaceutical company’s stock valued at $16,444,000 after purchasing an additional 2,267,632 shares during the last quarter. AXA S.A. purchased a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $1,430,000. Hsbc Holdings PLC increased its position in shares of Sangamo Therapeutics by 15.6% in the 3rd quarter. Hsbc Holdings PLC now owns 52,297 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 7,059 shares during the last quarter. Finally, New Harbor Financial Group LLC purchased a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $51,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on SGMO shares. HC Wainwright dropped their price objective on shares of Sangamo Therapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 3rd. Wells Fargo & Company dropped their price objective on shares of Sangamo Therapeutics from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 4th. Royal Bank of Canada dropped their price objective on shares of Sangamo Therapeutics from $22.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, February 23rd. Wedbush upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Monday, February 27th. Finally, Bank of America cut shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $8.00 to $5.00 in a report on Friday, January 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.83.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $2.26 on Friday. The stock has a market cap of $380.76 million, a P/E ratio of -1.81 and a beta of 1.17. The firm has a fifty day moving average price of $3.17 and a 200 day moving average price of $3.92. Sangamo Therapeutics, Inc. has a 1-year low of $2.13 and a 1-year high of $6.42.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. The firm had revenue of $27.23 million during the quarter, compared to analysts’ expectations of $26.86 million. Sangamo Therapeutics had a negative net margin of 172.76% and a negative return on equity of 61.19%. Sangamo Therapeutics’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) EPS. Sell-side analysts expect that Sangamo Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Sangamo Therapeutics Profile

(Get Rating)

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.